Trial Search Results
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).
Stanford is currently not accepting patients for this trial.
Center for International Blood and Marrow Transplant Research
Collaborator: Medical College of Wisconsin
- Behavioral: ePRO survey
In order to be eligible to participate on this study, an individual must meet all of the
1. Underwent an allogeneic HCT for MDS on the 10-CMSMDS-1 protocol
2. Prior consent to research and future contact by the CIBMTR
3. Ability to provide RCI BMT protocol 17-ePRO signed and dated informed consent form
4. Age ≥55 years at time of transplant
5. Fluent in English or Spanish
6. Greater than 6 months post-HCT
An individual who meets any of the following criteria will be excluded from participation
on this study.
1. No access to an internet browser or email account
2. Within 6 months of first HCT for MDS on the 10-CMSMDS-1 protocol
Ages Eligible for Study
55 Years - N/A
Genders Eligible for Study